TPOXX® Antiviral Treatment (Tecovirimat)

Concepts

• antivirals
• monkeypox
• antiviral treatment
• small supply of tpoxx
• drug tecovirimat
• treatment of severe cases of monkeypox
• supply of tecovirimat
• tecovirimat
• tpoxx
• monkeypox virus

Location

United Kingdom: UK

Description

The monkeypox virus belongs to a family of viruses called orthopox viruses and the drug Tecovirimat is an antiviral designed specifically to treat viral infections of this kind. In the current outbreak, Tecovirimat has been successfully used to treat patients with the most severe presentations of monkeypox virus infection. This contract is for a small supply of TPOXX® Antiviral Treatment (Tecovirimat) for the treatment of severe cases of Monkeypox in the UK.

Total Quantity or Scope

Supply of Tecovirimat antiviral treatment

Award Detail

Award Criteria

CPV Codes

• 33651400 - Antivirals for systemic use

Legal Justification

Negotiated procedure without a notice:Regulation 32(2)(b)(ii)This contract is for a small supply of TPOXX® Antiviral Treatment (Tecovirimat) for the treatment of severe cases of monkeypox in the UK.The procurement was initiated on the basis that Regulation 32(2)(b)(ii) was applicable in the circumstances that prevailed. This permits the use of a direct award where competition is absent for technical reasons. That is the situation that applies here and as a result a competitive procurement exercise could not have been conducted.The monkeypox virus belongs to a family of viruses called orthopox viruses. The drug Tecovirimat is an antiviral designed specifically to treat viral infections of this kind. There was no reasonable alternative or substitute available to the authority. This antiviral is the only product with authorisation from the MHRA for the treatment of monkeypox and Meridian Medical Technologies has exclusive right to supply the product to the UK. Therefore, this was the only option available within the market for the UK to procure an effective treatment against the current monkeypox outbreak.

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. ** Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate the price per dose. Publication of this information would therefore: (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vendors; and (iii) impact fair competition between vendors.